Revumenib in Combination With 7+3 + Midostaurin in AML

Status Not yet recruiting

Clinical Trial Summary

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). The names of the study drugs involved in this study are: - Revumenib (SNDX-5613) (a type of menin inhibitor) - Midostaurin (a type of multi-kinase including FLT3 inhibitor) - Cytarabine (a type of antineoplastic agent) - Daunorubicin (a type of antineoplastic agent)

Clinical Trial Description

This is a single arm open label phase I trial of the menin inhibitor, revumenib, in combination with cytarabine and daunorubicin (7+3) chemotherapy and the multikinase inhibitor midostaurin for the frontline treatment of Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML). Investigators are trying to determine the highest dose of revumenib that can be given safely in combination with these chemotherapy drugs. Treatment consists of 1-2 cycles of so-called "induction treatment" (initial chemotherapy to induce a remission of the leukemia). This "induction treatment" consists of revumenib + 7+3 (7 days of cytarabine + 3 days of daunorubicin) chemotherapy + midostaurin. The U.S. Food and Drug Administration (FDA) has not approved the combination of revumenib, cytarabine, daunorubicin, and midostaurin as a treatment for AML. The research study procedures include screening for eligibility, study treatment visits, blood and urine tests, bone marrow biopsies, and electrocardiograms (ECGs). Participants will receive study treatment as long as there are no serious side effects and the disease does not progress. The trial will include up to 12 participants in dose finding phase and 10 additional participants in the dose expansion phase for a total participant number of 22 participants. Syndax Pharmaceuticals is supporting this research study by supply revumenib (SNDX-5613). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06313437
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact	Maximilian Stahl, MD
Phone	617-582-7386
Email	maximilian_stahl@dfci.harvard.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	September 2024
Completion date	March 2, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05691608` - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2	N/A
Recruiting	`NCT04092803` - Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu	N/A
Active, not recruiting	`NCT02530463` - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome	Phase 2
Completed	`NCT00948064` - Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Phase 2
Completed	`NCT04474678` - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")	N/A
Terminated	`NCT00801931` - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders	Phase 1/Phase 2
Recruiting	`NCT03948529` - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation	Phase 2
Completed	`NCT01682226` - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies	Phase 2
Completed	`NCT00003270` - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	Phase 2
Active, not recruiting	`NCT02723994` - A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia	Phase 2
Terminated	`NCT02469415` - Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)	Phase 2
Recruiting	`NCT04856215` - 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia	Phase 2
Recruiting	`NCT06155188` - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia	N/A
Completed	`NCT00001637` - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults	Phase 2
Active, not recruiting	`NCT04188678` - Resiliency in Older Adults Undergoing Bone Marrow Transplant	N/A
Completed	`NCT02910583` - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)	Phase 2
Completed	`NCT01212926` - Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain	N/A
Terminated	`NCT00014560` - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Phase 1
Recruiting	`NCT04977024` - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer	Phase 2
Recruiting	`NCT05866887` - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia	N/A